RAYMOND DENNIS PRATT
Medical Practice in Baltimore, MD
License number
Pennsylvania MD424127
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
2
Baltimore, MD 21202
Pennsylvania
Pennsylvania
Personal information
See more information about RAYMOND DENNIS PRATT at radaris.comName
Address
Phone
480 Stonehedge Ln, Mechanicsburg, PA 17055
337 Abel Rd, Wrightsville, PA 17368
1078 Woodside Ave, Ellwood City, PA 16117
1470 Trance Dr, Pittsburgh, PA 15234
208 E Chase St, Baltimore, MD 21202
Professional information
Dr. Raymond D Pratt - MD (Doctor of Medicine)
Hospitals:
34166 State St, Farmington 48335
208 E Chase St, Baltimore 21202
34166 State St, Farmington 48335
208 E Chase St, Baltimore 21202
208 E Chase St, Baltimore 21202
34166 State St, Farmington 48335
208 E Chase St, Baltimore 21202
Education:
Medical Schools
University of Illinois At Chicago / College of Medicine
Graduated: 1976
University of Illinois At Chicago / College of Medicine
Graduated: 1976
Methods And Compositions Using Cholinesterase Inhibitors
US Patent:
2011005, Mar 3, 2011
Filed:
Oct 12, 2010
Appl. No.:
12/902534
Inventors:
John Ieni - Bloomfield NJ, US
Raymond Pratt - Baltimore MD, US
Raymond Pratt - Baltimore MD, US
Assignee:
Eisai R&D Management Co., Ltd. - Tokyo
International Classification:
A61K 31/445, A61K 31/13, A61P 25/28, A61P 25/16
US Classification:
514319, 514662
Abstract:
The invention provides methods for treating and/or preventing Alzheimer's disease, psychiatric illnesses, encephalitis, meningitis, fetal alcohol syndrome, Karsakoff's syndrome, anoxic brain injury, cardiopulmonary resuscitation injuries, diabetes, Sjogren's syndrome, mental retardation, developmental delay, menopause, strokes, macular degeneration, neuronal loss associated with macular degeneration, sleep disorders, severe Alzheimer's disease, jet lag, post-traumatic stress disorder, anxiety disorders, panic attacks, obsessive-compulsive disorder, amnesia, and other disorders by administering to a patient in need thereof at least one cholinesterase inhibitor. The invention also provides novel pharmaceutical compositions that can be administered to the eyes or to the nose of patients. In one embodiment, the cholinesterase inhibitor is donepezil, a stereoisomer thereof and/or a pharmaceutically acceptable salt thereof. In other embodiments, the cholinesterase inhibitor can be one or more of phenserine, tolserine, phenethylnorcymserine, ganstigmine, epastigmine, tacrine, physostigmine, pyridostigmine, neostigmine, rivastigmine, galantamine, citicoline, velnacrine, huperzine, metrifonate, heptastigmine, edrophonium, TAK-147, T-82, and upreazine.
Methods And Compositions Using Cholinesterase Inhibitors
US Patent:
2006001, Jan 26, 2006
Filed:
Nov 16, 2004
Appl. No.:
10/988600
Inventors:
John Ieni - Bloomfield NJ, US
Raymond Pratt - Baltimore MD, US
Raymond Pratt - Baltimore MD, US
Assignee:
Eisai Co., Ltd. - Tokyo
International Classification:
A61L 9/04, A61K 9/70, A61K 31/13
US Classification:
424045000, 424449000, 514662000
Abstract:
The invention provides methods for treating and/or preventing Alzheimer's disease, psychiatric illnesses, encephalitis, meningitis, fetal alcohol syndrome, Karsakoff's syndrome, anoxic brain injury, cardiopulmonary resuscitation injuries, diabetes, Sjogren's syndrome, mental retardation, developmental delay, menopause, strokes, macular degeneration, neuronal loss associated with macular degeneration, sleep disorders, severe Alzheimer's disease, jet lag, post-traumatic stress disorder, anxiety disorders, panic attacks, obsessive-compulsive disorder, amnesia, and other disorders by administering to a patient in need thereof at least one cholinesterase inhibitor. The invention also provides novel pharmaceutical compositions that can be administered to the eyes or to the nose of patients. In one embodiment, the cholinesterase inhibitor is donepezil, a stereoisomer thereof and/or a pharmaceutically acceptable salt thereof. In other embodiments, the cholinesterase inhibitor can be one or more of phenserine, tolserine, phenethylnorcymserine, ganstigmine, epastigmine, tacrine, physostigmine, pyridostigmine, neostigmine, rivastigmine, galantamine, citicoline, velnacrine, huperzine, metrifonate, heptastigmine, edrophonium, TAK-147, T-82, and upreazine.
Methods And Compositions Using Cholinesterase Inhibitors
US Patent:
2009004, Feb 12, 2009
Filed:
Aug 15, 2008
Appl. No.:
12/192826
Inventors:
John Ieni - Bloomfield NJ, US
Raymond Pratt - Baltimore MD, US
Raymond Pratt - Baltimore MD, US
Assignee:
Eisai Co., Ltd. - Tokyo
International Classification:
A61K 31/445
US Classification:
514319
Abstract:
The invention provides methods for treating and/or preventing Alzheimer's disease, psychiatric illnesses, encephalitis, meningitis, fetal alcohol syndrome, Karsakoff's syndrome, anoxic brain injury, cardiopulmonary resuscitation injuries, diabetes, Sjogren's syndrome, mental retardation, developmental delay, menopause, strokes, macular degeneration, neuronal loss associated with macular degeneration, sleep disorders, severe Alzheimer's disease, jet lag, post-traumatic stress disorder, anxiety disorders, panic attacks, obsessive-compulsive disorder, amnesia, and other disorders by administering to a patient in need thereof at least one cholinesterase inhibitor. The invention also provides novel pharmaceutical compositions that can be administered to the eyes or to the nose of patients. In one embodiment, the cholinesterase inhibitor is donepezil, a stereoisomer thereof and/or a pharmaceutically acceptable salt thereof. In other embodiments, the cholinesterase inhibitor can be one or more of phenserine, tolserine, phenethylnorcymserine, ganstigmine, epastigmine, tacrine, physostigmine, pyridostigmine, neostigmine, rivastigmine, galantamine, citicoline, velnacrine, huperzine, metrifonate, heptastigmine, edrophonium, TAK-147, T-82, and upreazine.
Methods And Compositions Using Cholinesterase Inhibitors
US Patent:
2009004, Feb 12, 2009
Filed:
Aug 15, 2008
Appl. No.:
12/192856
Inventors:
John Ieni - Bloomfield NJ, US
Raymond Pratt - Baltimore MD, US
Raymond Pratt - Baltimore MD, US
Assignee:
Eisai Co., Ltd. - Tokyo
International Classification:
A61K 31/445
US Classification:
514319
Abstract:
The invention provides methods for treating and/or preventing Alzheimer's disease, psychiatric illnesses, encephalitis, meningitis, fetal alcohol syndrome, Karsakoff's syndrome, anoxic brain injury, cardiopulmonary resuscitation injuries, diabetes, Sjogren's syndrome, mental retardation, developmental delay, menopause, strokes, macular degeneration, neuronal loss associated with macular degeneration, sleep disorders, severe Alzheimer's disease, jet lag, post-traumatic stress disorder, anxiety disorders, panic attacks, obsessive-compulsive disorder, amnesia, and other disorders by administering to a patient in need thereof at least one cholinesterase inhibitor. The invention also provides novel pharmaceutical compositions that can be administered to the eyes or to the nose of patients. In one embodiment, the cholinesterase inhibitor is donepezil, a stereoisomer thereof and/or a pharmaceutically acceptable salt thereof. In other embodiments, the cholinesterase inhibitor can be one or more of phenserine, tolserine, phenethylnorcymserine, ganstigmine, epastigmine, tacrine, physostigmine, pyridostigmine, neostigmine, rivastigmine, galantamine, citicoline, velnacrine, huperzine, metrifonate, heptastigmine, edrophonium, TAK-147, T-82, and upreazine.
Novel Combination Of Drugs As Antidepressant
US Patent:
2007005, Mar 8, 2007
Filed:
Sep 20, 2006
Appl. No.:
11/523803
Inventors:
Kazuo Sakai - Tokyo, JP
John Ieni - Bloomfield NJ, US
Raymond Pratt - Baltimore MD, US
John Ieni - Bloomfield NJ, US
Raymond Pratt - Baltimore MD, US
Assignee:
Eisai R & D Management Co., Ltd. - Tokyo
International Classification:
A61K 31/165, A61K 31/137, A61K 31/381, A61K 31/405, A61K 9/20
US Classification:
424464000, 514419000, 514620000, 514649000
Abstract:
A novel antidepressant composition of a cholinesterase inhibitor in combination with a selective serotonin reuptake inhibitor, milnacipran or duloxetine is disclosed, which has a significantly high therapeutic effect as compared with conventional antidepressants. The therapeutic method using a cholinesterase inhibitor in combination with a selective serotonin reuptake inhibitor, milnacipran or duloxetine is beneficial for the treatment of depression, in particular, refractory depression.